DaVita (NYSE:DVA – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.
Several other analysts have also recently commented on DVA. Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. Finally, Barclays lifted their price target on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus price target of $166.33.
DaVita Stock Down 0.5 %
DaVita (NYSE:DVA – Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, research analysts expect that DaVita will post 10.76 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Copia Wealth Management bought a new stake in DaVita during the fourth quarter worth approximately $30,000. SBI Securities Co. Ltd. acquired a new position in DaVita during the 4th quarter worth $41,000. Coppell Advisory Solutions LLC boosted its holdings in DaVita by 50.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock valued at $45,000 after acquiring an additional 100 shares during the period. Canada Post Corp Registered Pension Plan bought a new position in shares of DaVita in the fourth quarter worth about $55,000. Finally, Quarry LP acquired a new position in shares of DaVita during the 3rd quarter worth about $60,000. Institutional investors and hedge funds own 90.12% of the company’s stock.
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More
- Five stocks we like better than DaVita
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Upcoming IPO Stock Lockup Period, Explained
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- What is the Australian Securities Exchange (ASX)
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.